Trials / Conditions / Schizoaffective Disorder

Schizoaffective Disorder

538 registered clinical trials studyying Schizoaffective Disorder — 43 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Shared Decision Making for Antipsychotic Medications NCT05416658	New York State Psychiatric Institute	N/A
Not Yet Recruiting	Enhancing Veteran-Clinical Collaboration in VA PRRCs NCT06898879	VA Office of Research and Development	N/A
Not Yet Recruiting	Cognitive Strategies in Early Psychosis 2 NCT07263022	University of Minnesota	Phase 3
Enrolling By Invitation	Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization NCT07130500	Stanford University	N/A
Not Yet Recruiting	LRFN5 and OLFM4 in Schizoaffective Disorder NCT07447960	Elazığ Mental Health and Diseases Hospital	—
Not Yet Recruiting	Improving Health Literacy in Patients With Schizophrenia Spectrum Disorder NCT07488156	Louisiana State University Health Sciences Center in New Orleans	N/A
Recruiting	Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Sp NCT07395206	Charite University, Berlin, Germany	N/A
Not Yet Recruiting	Impact of Medication Education on Adherence and Side Effects NCT07374588	Cumhuriyet University	N/A
Recruiting	Synergy Between Physical Activity and Outdoor Green Environments to Reduce the Intensity of Negative Symptoms NCT07058389	Centre Hospitalier Universitaire de Saint Etienne	N/A
Recruiting	Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy NCT07098169	University of California, San Diego	N/A
Recruiting	A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Re NCT07105111	Neurocrine Biosciences	Phase 4
Not Yet Recruiting	Therapeutic Improvement in People With Schizophrenia Undergoing tACS/CBTp (Transcranial Alternating Current St NCT06889025	Felicia Iftene	N/A
Recruiting	Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders NCT07043803	University of Pittsburgh	N/A
Recruiting	Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness (R33) NCT06865937	University of California, San Diego	N/A
Recruiting	Exercise and Olanzapine-samidorphan NCT06740890	New York State Psychiatric Institute	Phase 4
Completed	Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder NCT07116694	BioXcel Therapeutics Inc	Phase 2
Recruiting	Magnetic Seizure Therapy for Schizophrenia - Trial NCT06672588	Centre for Addiction and Mental Health	N/A
Withdrawn	A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With NCT06878833	Lyndra Inc.	Phase 3
Recruiting	40 Hz Visual Stimulation as an Intervention in Schizophrenia NCT06907420	Technical University of Munich	N/A
Active Not Recruiting	Cognitive Rehabilitation With Immersive Virtual Reality (IVR) in Schizophrenia: a Pilot Randomized Waiting Lis NCT07427485	Azienda Sanitaria Locale Napoli 3 Sud, UOCSM Torre del Greco	N/A
Recruiting	Enhancing Rehabilitation for Veterans With Serious Mental Illness NCT06586164	VA Office of Research and Development	N/A
Recruiting	Anticholinergic Deprescription in Schizophrenia NCT06562608	Deepak K. Sarpal, M.D.	Phase 4
Recruiting	Decision-Making in Schizophrenia: A Combined Neuroimaging and Experience Sampling Study NCT06745479	Rutgers, The State University of New Jersey	N/A
Not Yet Recruiting	Obstructive Sleep Apnea Treatment in Serious Mental Illness NCT05457127	University of California, San Diego	N/A
Not Yet Recruiting	Individual Placement and Support and/or Cognitive Remediation Therapy Added to TAU in Patients With Early Schi NCT03974620	Pakistan Institute of Living and Learning	N/A
Enrolling By Invitation	Open Label Extension Study of NCT06221852 NCT06558201	Mclean Hospital	N/A
Recruiting	Integrative Neuro-social Cognitive Strategy Programme for Instilling REcovery (INSPIRE) a Community-Based Cogn NCT06286202	Singapore Institute of Technology	N/A
Recruiting	Cerebellar Modulation of Cognition in Psychosis NCT06107764	Mclean Hospital	N/A
Recruiting	Effectiveness of Motivation Skills Training (MST) NCT05805397	Columbia University	N/A
Recruiting	Effect of Neuroplasticity Modulation in tDCS Treatment Response Among Schizophrenia Patients With Auditory Hal NCT04629352	National Institute of Mental Health and Neuro Sciences, India	N/A
Active Not Recruiting	Optimizing CBSST With Executive Function Training for Schizophrenia NCT06251193	University of California, San Diego	N/A
Recruiting	Prediction and Intervention Effect of Rehabilitation Status for Severe Mental Disorder Patients Based on Multi NCT06904079	Shanghai Mental Health Center	N/A
Recruiting	Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder NCT06221852	Mclean Hospital	N/A
Recruiting	Enhanced Coordinated Specialty Care for Early Psychosis NCT06071858	Mclean Hospital	N/A
Terminated	Horyzons: Implementation and Integration in Clinical Practice NCT06002958	University of North Carolina, Chapel Hill	N/A
Recruiting	Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine NCT06003036	Deepak K. Sarpal, M.D.	N/A
Completed	NST-SPARK: Preliminary Study of an Augmented Reality (AR) App Delivering Recovery-Oriented Cognitive Therapy f NCT06653829	North Shore Therapeutics, Inc.	N/A
Withdrawn	Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in t NCT05974527	Brigham and Women's Hospital	Phase 4
Recruiting	The Efficacy of Metacognitive Skills Training in the Context of Forensic Psychiatric Care NCT06005766	University of Jyvaskyla	N/A
Unknown	SUCCEED Africa: Support, Comprehensive Care and Empowerment of People With Psychosocial Disabilities NCT06007105	London School of Hygiene and Tropical Medicine	N/A
Completed	Motivation Skills Training for Schizophrenia NCT05746455	Columbia University	N/A
Active Not Recruiting	EPI-MINN: Targeting Cognition and Motivation - National NCT05877716	University of Minnesota	N/A
Recruiting	Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Epi NCT05890183	University of California, Los Angeles	N/A
Completed	Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tar NCT05859698	Neurocrine Biosciences	Phase 4
Completed	Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment NCT06664138	Yeongseok Yun	Phase 4
Completed	Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005 NCT05779241	Lyndra Inc.	Phase 3
Recruiting	Prebiotic Treatment in People With Schizophrenia NCT05527210	University of Maryland, Baltimore	N/A
Recruiting	Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services NCT06740383	Beth Israel Deaconess Medical Center	—
Unknown	Characterizing Response to Antipsychotics in Schizophrenia NCT06159322	The Royal Ottawa Mental Health Centre	—
Unknown	Accelerated TMS in Psychosis NCT05567848	Beth Israel Deaconess Medical Center	Phase 1 / Phase 2
Completed	Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III NCT05658510	BioXcel Therapeutics Inc	Phase 3
Completed	Service User and Staff Views on Digital Remote Monitoring for Psychosis NCT05670197	Manchester Academic Health Science Centre	—
Unknown	Enhancing Educational and Vocational Recovery in Adolescents and Young Adults With Early Psychosis Through Sup NCT05824117	Charite University, Berlin, Germany	N/A
Recruiting	Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders NCT06423651	Universitat Autonoma de Barcelona	N/A
Unknown	Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia NCT02533232	Pakistan Institute of Living and Learning	Phase 1
Completed	State Representation in Early Psychosis - Project 4 NCT05664594	University of Minnesota	N/A
Completed	Remote State Representation in Early Psychosis NCT05538832	University of Minnesota	EARLY_Phase 1
Completed	Adapting and Examining Collaborative Decision Skills Training Among Veterans With Serious Mental Illness NCT04324944	VA Office of Research and Development	N/A
Completed	Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness NCT05660070	University of California, San Diego	N/A
Withdrawn	Exercise Target Brain Oscillations in Psychosis NCT05338424	University of Minnesota	—
Completed	Luteolin for the Treatment of People With Schizophrenia NCT05204407	University of Maryland, Baltimore	N/A
Completed	Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot Study NCT05380583	Mclean Hospital	N/A
Recruiting	Development of a Model for Digital Monitoring of the Mental State of the Hospitalized Patient NCT06182787	Sheba Medical Center	—
Completed	Study by Electroencephalography of the Link Between the Lack of Self-compassion and the Disorder of Empathy in NCT05464563	Centre Hospitalier Henri Laborit	N/A
Recruiting	Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial NCT05208190	New York State Psychiatric Institute	Phase 4
Completed	Academic-Community EPINET (AC-EPINET) NCT04497857	Indiana University	N/A
Terminated	Sodium Nitroprusside in Early Course Schizophrenia NCT04986072	Beth Israel Deaconess Medical Center	Phase 2
Recruiting	CLOZAPINE Response in Biotype-1 NCT04580134	University of Texas Southwestern Medical Center	Phase 4
Recruiting	Synbiotic Compound to Reduce Symptoms of Schizophrenia NCT04226898	Sheppard Pratt Health System	Phase 2
Completed	State Representation in Early Psychosis NCT05273164	University of Minnesota	—
Completed	Mobile Self-Tracking of Mental Health NCT05023252	VA Office of Research and Development	N/A
Completed	Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings NCT05030272	Wake Forest University Health Sciences	N/A
Completed	Memantine Augmentation of Targeted Cognitive Training in Schizophrenia NCT04857983	University of California, San Diego	Phase 2 / Phase 3
Completed	eMove - Dance/Movement Therapy Study NCT05712928	Drexel University	N/A
Completed	Feasibility of a Novel Process-based Treatment for Patients With Psychosis NCT04874974	Max-Planck-Institute of Psychiatry	N/A
Active Not Recruiting	The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosi NCT04916626	Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital	N/A
Completed	M1 Schizophrenia PET Study NCT05105542	Yale University	Phase 1
Completed	Effect of Individual Cognitive Stimulation at Home in Adults With Psychotic Disorders NCT04783285	CEDIARA - Assoc. Solidariedade Social de Ribeira de Fráguas	N/A
Completed	Horyzons: Implementation in Clinical Practice NCT04673851	University of North Carolina, Chapel Hill	N/A
Withdrawn	Effectiveness and Mechanisms of Recovery Oriented Cognitive Therapy NCT05140135	University of Pennsylvania	N/A
Completed	Efficacy of Personalizing Cognitive Remediation for Schizophrenia by Targeting Impairments in Early Auditory P NCT04554121	Columbia University	N/A
Completed	Neuromodulation of Social Cognitive Circuitry in People With Schizophrenia Spectrum Disorders NCT04418011	Centre for Addiction and Mental Health	N/A
Completed	Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia NCT04414930	University of California, San Diego	Phase 2
Completed	Feasibility Electrical Stimulation Study for Visual Hallucinations NCT04870710	Beth Israel Deaconess Medical Center	N/A
Completed	Families With Substance Use and Psychosis: A Pilot Study NCT04284813	Mclean Hospital	N/A
Completed	ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention NCT04298450	Centre for Addiction and Mental Health	N/A
Unknown	Assessing the Effect of Compensatory Cognitive Intervention Among People With Severe Mental Illness NCT04551027	Shalvata Mental Health Center	N/A
Completed	Safety and Efficacy of Virtual Reality Mindfulness in Patients With Psychosis NCT05784948	Chonbuk National University Hospital	N/A
Unknown	Survey on Pre-ECT Evaluation and ECT Application NCT04335916	Klinički Bolnički Centar Zagreb	—
Completed	BXCL501 for Agitation in Schizophrenia NCT03708315	Yale University	Phase 1
Completed	Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia NCT04268303	BioXcel Therapeutics Inc	Phase 3
Completed	The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia NCT04013555	University of Maryland, Baltimore	Phase 1 / Phase 2
Completed	Evaluation of mHealth for Serious Mental Illness NCT04068467	University of Washington	N/A
Completed	Early Psychosis Intervention - Spreading Evidence-based Treatment NCT03919760	Centre for Addiction and Mental Health	N/A
Completed	Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial NCT04173572	University of North Carolina, Chapel Hill	N/A
Unknown	Cognitive Behavioral Therapy for Insomnia (CBT-I) in Schizophrenia(SLEEPINS) NCT04144231	Helsinki University Central Hospital	N/A
Unknown	Estradiol as add-on to Antipsychotics NCT04093518	Tangent Data	Phase 3
Unknown	Comparing Cognitive Remediation Approaches for Schizophrenia NCT04123223	Wesleyan University	N/A
Completed	Theta tACS During Working Memory Training: A Pilot Study of the Effects on Negative Symptoms of Schizophrenia NCT04545294	Tri-Service General Hospital	N/A
Completed	Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness NCT04011280	University of California, San Diego	Phase 4
Completed	Prebiotic Treatment in People With Schizophrenia - Pilot Study NCT03617783	University of Maryland, Baltimore	Phase 4
Completed	Maximizing the Impact of Neuroplasticity Using Transcranial Electrical Stimulation Study 2 NCT03896438	University of Minnesota	N/A
Suspended	Cognitive Remediation for Coordinated Specialty Care NCT03930251	New York State Psychiatric Institute	N/A
Completed	Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI) NCT03873337	Rutgers, The State University of New Jersey	N/A
Completed	Cognitive Adaption Training-Effectiveness in Real-world Settings and Mechanism of Action (CAT-EM) NCT03829280	The University of Texas Health Science Center at San Antonio	N/A
Completed	Mobile CBT for Negative Symptoms NCT03621774	University of California, San Diego	N/A
Completed	Overcoming Psychomotor Slowing in Psychosis (OCoPS-P) NCT03921450	University of Bern	N/A
Completed	Improving Visual Attention in Schizophrenia NCT03880227	The University of Texas at Dallas	N/A
Completed	Verbal Memory Training Using Virtual Reality in Schizophrenia NCT04251195	The Royal Ottawa Mental Health Centre	N/A
Completed	Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder. NCT03510741	Pakistan Institute of Living and Learning	Phase 2
Recruiting	Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates NCT03495024	Corporal Michael J. Crescenz VA Medical Center	Phase 4
Completed	A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patie NCT03751488	Luye Pharma Group Ltd.	Phase 1
Completed	Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life NCT03757988	University of North Carolina, Chapel Hill	N/A
Completed	OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis NCT03390491	Center for Social Innovation, Massachusetts	N/A
Completed	Motivation and Skills Support (MASS) NCT03404219	Boston University Charles River Campus	N/A
Completed	Add-on HD Hf-tRNS Over Bilateral DLPFC for Treating Patients With Schizophrenia NCT04038788	Tri-Service General Hospital	N/A
Completed	Improving Accessibility and Personalization of CR for Schizophrenia NCT03576976	New York State Psychiatric Institute	N/A
Completed	Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder NCT03526354	University of Massachusetts, Worcester	Phase 4
Completed	Remediation of Visual Perceptual Impairments in People With Schizophrenia NCT03314129	University of Rochester	N/A
Completed	Assessment of Efficacy of a Psychological Therapy in Inpatients With a Schizophrenic Psychosis NCT03316664	Psychiatric University Hospital, Zurich	N/A
Completed	A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals NCT03568500	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 4
Completed	Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia NCT03860597	University of California, San Diego	Phase 4
Completed	Texting for Relapse Prevention NCT02819349	Center for Innovative Public Health Research	N/A
Completed	Feasibility and Relevance of High-Intensity Functional Training in Patients With First-Episode Psychosis NCT03409393	Rigshospitalet, Denmark	N/A
Completed	Stimulating the Brain to Improve Self-Awareness NCT03370341	The University of Texas at Dallas	N/A
Completed	Theta Burst Stimulation for Schizophrenia NCT03288779	Duke University	N/A
Completed	Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness NCT03062267	University of Washington	N/A
Completed	Neural Biomarkers of Clozapine Response NCT03076346	University of Pittsburgh	—
Completed	Improving Neurocognitive Deficits and Function in Schizophrenia With Transcranial Magnetic Stimulation NCT03037983	VA Office of Research and Development	N/A
Completed	The Effects of Bimodal tDCS on Illness Severity, Insight, Functional Outcomes, Neurocognition and HRV in Schiz NCT03701100	Tri-Service General Hospital	N/A
Completed	Lifestyle Intervention for Young Adults With Serious Mental Illness NCT02815813	Dartmouth-Hitchcock Medical Center	N/A
Completed	Virtual Reality Job Interview Training in Severe Mental Illness NCT03049813	University of Michigan	N/A
Completed	Minnesota Community-Based Cognitive Training in Early Psychosis NCT03079024	University of Minnesota	N/A
Unknown	Joint Crisis Plans or Crisis Cards for People With Severe Mental Disorders to Reduce Coercion in Psychiatric C NCT03240380	Universitätsklinikum Hamburg-Eppendorf	N/A
Completed	The Appeal and Impact of E-cigarettes in Smokers With SMI NCT03050853	Dartmouth-Hitchcock Medical Center	N/A
Unknown	Cognitive Behavioral Social Skills Training in Early Onset Psychosis NCT03261557	Hospital Clinic of Barcelona	N/A
Completed	Sulforaphane to Reduce Symptoms of Schizophrenia NCT02810964	Sheppard Pratt Health System	Phase 2
Completed	Sustainable Early Episode Clinic Study (SEEC) NCT03571685	Janssen Scientific Affairs, LLC	N/A
Completed	Comparing Thinking Skills for Work (TSW)Home Practice Program With Traditional TSW Program NCT03005574	Boston University Charles River Campus	N/A
Completed	Clinical Trial of AVL-3288 in Schizophrenia Patients NCT02978599	New York State Psychiatric Institute	Phase 1
Unknown	A Randomised Controlled Trial of Coenzyme Q10 in Patients With Schizophrenia and Schizoaffective Disorder NCT03576911	University of Dublin, Trinity College	N/A
Completed	Enhancing Cognitive Training Through Exercise Following a First Schizophrenia Episode NCT02823041	University of California, Los Angeles	N/A
Completed	Schizophrenia and the Gut Microbiome NCT02921243	University of Maryland, Baltimore	—
Withdrawn	Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia NCT03061136	Palo Alto Veterans Institute for Research	Phase 4
Completed	Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and NCT02901587	H. Lundbeck A/S	Phase 1
Completed	Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM) NCT02782442	University of Minnesota	N/A
Terminated	MEtformin and Lorcaserin for WeighT Loss in Schizophrenia NCT02796144	University of North Carolina, Chapel Hill	Phase 4
Completed	Mobile-Assisted Cognitive Behavior Therapy for Negative Symptoms in Schizophrenia NCT03179696	Eric Granholm	N/A
Completed	Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder NCT03043820	Iris Sommer	Phase 3
Recruiting	Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia NCT02639702	Centre for Addiction and Mental Health	Phase 4
Completed	The Effects of tDCS on Auditory Hallucination, Insight, Neurocognitive Function and HRV in Patients With Schiz NCT03388554	Tri-Service General Hospital	N/A
Completed	Remediation of Auditory Recognition in Schizophrenia With tDCS NCT02869334	New York State Psychiatric Institute	N/A
Completed	The Potential Efficacy of the Chinese Health Improvement Profile- A Pilot Clustered Randomised Controlled Tria NCT02453217	Wai-Tong Chien	N/A
Completed	Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers NCT02386605	VA Office of Research and Development	N/A
Completed	Research Into Antipsychotic Discontinuation and Reduction Trial NCT03559426	University College, London	Phase 4
Completed	Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study NCT02642029	Mclean Hospital	N/A
Terminated	A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia NCT02476708	Yale University	N/A
Unknown	Remote Monitoring and Support for Patients With Schizophrenia, Schizoaffective or Bipolar Disorder on Adherenc NCT02665611	Assuta Hospital Systems	N/A
Completed	Positive Emotions Program for Schizophrenia (PEPS) NCT02593058	Institut et Haute Ecole de la Santé la Source	N/A
Withdrawn	Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia NCT02661347	Northwell Health	N/A
Completed	Cannabidiol Treatment in Patients With Early Psychosis NCT02504151	Yale University	Phase 2
Completed	Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment With Antipsychotics NCT02573168	St. Joseph's Healthcare Hamilton	N/A
Completed	Video as a Tool to Improve Insight in Schizophrenia NCT02664129	University Hospital, Montpellier	N/A
Completed	Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophrenifor NCT03848234	Tangent Data	Phase 3
Completed	A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder NCT02636842	Alkermes, Inc.	Phase 1
Completed	Development of a Mobile System for Self-management of Schizophrenia (SOS) NCT01969500	Dartmouth-Hitchcock Medical Center	N/A
Completed	Modified Psychodynamic Psychotherapy for Patients With Schizophrenia NCT02576613	Charite University, Berlin, Germany	N/A
Completed	RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia) NCT02160249	London School of Hygiene and Tropical Medicine	N/A
Completed	Comparison of E-health vs. In-person Multi-Family Group (MFG) NCT02032680	VA Office of Research and Development	N/A
Completed	Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders NCT02930005	The University of Texas Health Science Center, Houston	Phase 2
Unknown	Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms NCT02529163	Centre for Addiction and Mental Health	N/A
Completed	Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia NCT02775864	New York State Psychiatric Institute	—
Completed	Building Employment Skills Through Therapy for Veterans NCT01992913	VA Office of Research and Development	N/A
Completed	Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness NCT02421965	Dartmouth-Hitchcock Medical Center	N/A
Completed	OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant NCT02415764	Center for Social Innovation, Massachusetts	Phase 1
Terminated	A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Ch NCT02462473	Janssen Research & Development, LLC	Phase 2
Completed	STimulation to Improve Auditory haLLucinations NCT02360228	University of North Carolina, Chapel Hill	N/A
Completed	Exercise and Cognitive Training NCT02326389	Boston University Charles River Campus	N/A
Unknown	A Pharmacokinetic Study of Paliperidone ER NCT02433717	National Taiwan University Hospital	Phase 4
Completed	A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia NCT01952041	Dartmouth-Hitchcock Medical Center	N/A
Completed	Task Sharing for the Care of Severe Mental Disorders in a Low-income Country NCT02308956	University of Cape Town	Phase 3
Completed	Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizo NCT02411526	Zogenix, Inc.	Phase 1
Completed	Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients NCT02188121	Mclean Hospital	Phase 4
Completed	Minocycline Augmentation to Clozapine NCT02124811	Emory University	Phase 4
Withdrawn	Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia NCT02197286	NYU Langone Health	Phase 2
Completed	Self-Management Training and Automated Telehealth to Improve SMI Health Outcomes NCT02188732	Dartmouth-Hitchcock Medical Center	N/A
Completed	Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia NCT02069392	University of Maryland, Baltimore	N/A
Unknown	Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs NCT02986490	University Hospital, Montpellier	N/A
Terminated	Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia NCT02234752	Sheppard Pratt Health System	Phase 2
Completed	Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia NCT02417142	University of Massachusetts, Worcester	Phase 4
Completed	Bioavailability of LY03004 and Risperdal® Consta® NCT02091388	Luye Pharma Group Ltd.	Phase 1
Completed	Prediction of Relapse in Schizophrenia/Schizoaffective Disorder With Smartphones and On-body Sensors NCT02224430	University of Alabama at Birmingham	—
Completed	Cognitive Remediation Therapy Within a Secure Forensic Setting NCT02360813	Central Mental Hospital	N/A
Unknown	Perceptual Deficits in Schizophrenia NCT02337439	VA Connecticut Healthcare System	N/A
Completed	Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia NCT02237235	Northwestern University	Phase 2
Completed	Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis NCT02566057	Northwell Health	N/A
Completed	An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophre NCT02186769	Luye Pharma Group Ltd.	Phase 1
Terminated	Prednisolone Addition for Patients With Recent-onset Psychotic Disorder NCT02949232	UMC Utrecht	Phase 4
Unknown	Electroconvulsive Therapy in Clozapine-resistant Schizophrenia NCT02159001	Niuvanniemi Hospital	N/A
Completed	Integrated Metacognitive Therapy in First Episode Psychosis NCT02131116	Indiana University	N/A
Completed	A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Ho NCT02085447	University Hospitals Cleveland Medical Center	N/A
Completed	rTMS in First Episode Psychosis NCT02131129	Indiana University	N/A
Completed	Psychosocial Intervention to Reduce Self-stigma and Improve Quality of Life Among People With Mental Illness i NCT03197168	University of Chile	N/A
Completed	D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions NCT01981759	NYU Langone Health	Phase 4
Completed	Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia NCT02034474	New York State Psychiatric Institute	Phase 4
Unknown	Measuring the Effect of Remote Monitoring of Treatment Adherence on the Risk of Re-admission of Ambulatory Sch NCT01729572	Shalvata Mental Health Center	N/A
Completed	Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia NCT01963676	University of North Carolina, Chapel Hill	N/A
Completed	Glutamate, Brain Connectivity and Duration of Untreated Psychosis NCT02034253	University of Alabama at Birmingham	—
Completed	Oxytocin and CBSST for People With Schizophrenia NCT01752712	University of Maryland, Baltimore	N/A
Completed	Pilot-trial of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia NCT02787122	Philipps University Marburg	N/A
Completed	RCT of Methotrexate Added to Treatment As Usual in Schizophrenia NCT02074319	Pakistan Institute of Living and Learning	Phase 1
Completed	Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode NCT02267070	University of California, Los Angeles	N/A
Completed	Simvastatin Addition for Patients With Recent-onset Schizophrenia NCT01999309	Iris Sommer	Phase 3
Completed	Neuroendocrine and Immune Response to Stress in Schizophrenia NCT01975584	University of Maryland, Baltimore	N/A
Terminated	Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations NCT02149823	Maria de las Mercedes Perez Rodriguez	Phase 1
Completed	Personalized and Scalable Cognitive Remediation Approaches NCT01945333	New York State Psychiatric Institute	N/A
Completed	Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME) NCT01992393	Case Western Reserve University	N/A
Completed	rTMS for Working Memory Deficits in Schizophrenia NCT01880255	Centre for Addiction and Mental Health	N/A
Completed	Get Moving and Get Well - Pilot Study NCT01884025	VA Office of Research and Development	N/A
Completed	Naltrexone for Antipsychotic-Induced Weight Gain NCT01866098	Yale University	N/A
Completed	Omega-3 Dietary Supplements in Schizophrenia NCT01786239	Delbert Robinson	N/A
Completed	Effectiveness of Adherence Therapy for Schizophrenia NCT01780116	The Hong Kong Polytechnic University	Phase 1 / Phase 2
Completed	Improving Care and Reducing Cost Study NCT02364544	Northwell Health	N/A
Terminated	Antipsychotic Effects on Brain Function in Schizophrenia NCT01913327	University of California, San Francisco	Phase 4
Completed	Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia NCT01793935	K.N. Roy Chengappa	N/A
Completed	Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths NCT01788774	Rovi Pharmaceuticals Laboratories	Phase 1
Unknown	Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Schizoaffective NCT02221635	Xijing Hospital	—
Completed	Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder NCT02055287	Luye Pharma Group Ltd.	Phase 1
Unknown	Navigated αTMS in Treatment-resistant Schizophrenia NCT01941251	Niuvanniemi Hospital	N/A
Completed	Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia NCT01794897	University of Pittsburgh	Phase 4
Completed	Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antip NCT01786369	Northwell Health	—
Completed	Lurasidone Effects on Tissue Glutamate in Schizophrenia NCT02199743	University of Texas Southwestern Medical Center	Phase 4
Unknown	Adherence and Quality of Life in People With Schizophrenia and Schizoaffective Disorder NCT01769014	Psychiatrische Dienste Graubuenden	—
Terminated	Contrasting Group Therapy Methods for Psychosis NCT01764568	University of British Columbia	N/A
Completed	Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) NCT01822418	Central Institute of Mental Health, Mannheim	Phase 4
Completed	Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents NCT01731119	University of North Carolina, Chapel Hill	Phase 2
Completed	Lifestyle Intervention for Diabetes and Weight Management in Psychosis NCT01828931	Centre for Addiction and Mental Health	N/A
Completed	Probiotics to Prevent Relapse After Hospitalization for Mania NCT01731171	Sheppard Pratt Health System	N/A
Completed	Kuvan in People With Schizophrenia and Schizoaffective Disorder NCT01706965	New York State Psychiatric Institute	Phase 1 / Phase 2
Completed	Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder NCT01658150	Icahn School of Medicine at Mount Sinai	N/A
Completed	Understanding How Cognitive Remediation Works NCT01683539	Boston University Charles River Campus	N/A
Completed	Brain Imaging, Cognitive Enhancement and Early Schizophrenia NCT01561859	Beth Israel Deaconess Medical Center	N/A
Completed	Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy NCT01609153	Heinrich-Heine University, Duesseldorf	Phase 4
Completed	PTSD (PostTraumatic Stress Disorder) Services for Veterans With SMI (Severe Mental Illness) NCT01542229	VA Office of Research and Development	N/A
Terminated	Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia NCT01929889	Northwestern University	Phase 4
Completed	Antipsychotics and Risk of Hyperglycemic Emergencies NCT02582736	Canadian Network for Observational Drug Effect Studies, CNODES	—
Completed	POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia NCT01450514	PharmaNeuroBoost N.V.	Phase 2
Completed	Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia NCT02137993	HK inno.N Corporation	Phase 4
Unknown	N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia NCT01474395	Nathan Kline Institute for Psychiatric Research	Phase 2
Completed	Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Dis NCT01596608	Centre for Addiction and Mental Health	N/A
Completed	Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia NCT01481883	The Alfred	Phase 4
Completed	RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder NCT01490086	Reviva Pharmaceuticals	Phase 2
Completed	Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders NCT01487668	VA Office of Research and Development	N/A
Terminated	Social Cognition in Longstanding Psychosis NCT01624831	University of Arizona	—
Completed	Reducing Internalized Stigma in People With Serious Mental Illness NCT01259427	VA Office of Research and Development	Phase 2
Completed	Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia NCT01431092	Lone Baandrup	Phase 4
Completed	Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia NCT01394471	University of North Carolina, Chapel Hill	Phase 1
Unknown	F-18 Altanserin PET Study of Patients Receiving Clozapine NCT01398189	Seoul National University Bundang Hospital	N/A
Completed	Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorde NCT01423916	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 1
Completed	Nicotinic Receptors and Schizophrenia NCT01400477	University of Colorado, Denver	Phase 2
Recruiting	Brain Health and Exercise in Schizophrenia NCT01392885	BC Mental Health and Addictions Research Institute	—
Completed	L-arginine add-on Therapy in Patients With Schizophrenia NCT02398279	Hacettepe University	N/A
Completed	Salsalate as an Adjunctive Treatment for Patients With Schizophrenia NCT01578486	University of Massachusetts, Worcester	Phase 4
Completed	The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia NCT01339858	Indiana University	Phase 4
Completed	Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen NCT01555814	Birte Glenthoj	N/A
Completed	Optimization of Treatment and Management of Schizophrenia in Europe NCT01248195	Rene Kahn	Phase 4
Completed	Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders NCT01519557	New York State Psychiatric Institute	EARLY_Phase 1
Completed	Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia NCT02354001	The Alfred	Phase 4
Unknown	Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective NCT01320982	Sheba Medical Center	Phase 3
Unknown	Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder NCT01280305	Sheba Medical Center	Phase 3
Completed	A Comparison of Long-acting Injectable Medications for Schizophrenia NCT01136772	New York State Psychiatric Institute	Phase 4
Unknown	Pregnenolone and L-theanine Augmentation in the Treatment for Schizophrenia and Schizoaffective Disorders NCT01831986	Sha'ar Menashe Mental Health Center	N/A
Completed	Brain Circuits in Schizophrenia and Smoking NCT01425684	University of Maryland, Baltimore	—
Completed	Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States NCT01425671	University of Maryland, Baltimore	—
Completed	An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status NCT01309373	Janssen-Cilag, S.A.	—
Unknown	The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy NCT01215383	Ziv Hospital	—
Completed	Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis NCT01216891	Research Foundation for Mental Hygiene, Inc.	N/A
Terminated	Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia NCT01420575	VA Nebraska Western Iowa Health Care System	N/A
Completed	Effectiveness of Ziprasidone for Patients With Schizophrenia NCT01198353	Soonchunhyang University Hospital	Phase 4
Completed	A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Sch NCT01193153	Janssen Scientific Affairs, LLC	Phase 3
Completed	Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia NCT01292577	University of Pittsburgh	Phase 1 / Phase 2
Completed	Randomized Double Blind Placebo Control Study in Patients with Schizophrenia NCT01602029	Pakistan Institute of Living and Learning	Phase 2
Unknown	Reduction of Cardiovascular Risk in Severe Mental Illness NCT01182012	Consorci Hospitalari de Vic	Phase 4
Completed	A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder NCT01143090	Sumitomo Pharma America, Inc.	Phase 3
Completed	Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia NCT01242371	Sheppard Pratt Health System	N/A
Completed	An Integrated Program for the Treatment of First Episode of Psychosis NCT01321177	Northwell Health	N/A
Completed	Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis NCT01196286	University of Arizona	N/A
Completed	A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switc NCT01143077	Sumitomo Pharma America, Inc.	Phase 3
Completed	Nonconvulsive Electrotherapy: a Proof-of-concept Trial NCT01065597	University of Maryland, College Park	Phase 1
Unknown	Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia NCT01324167	Taipei Medical University WanFang Hospital	—
Completed	Smoking Cessation for Veterans With Severe and Persistent Mental Illness NCT00960375	US Department of Veterans Affairs	Phase 2 / Phase 3
Completed	Factors Association With Poor Physical Function in Older Adults With Schizophrenia NCT01092598	University of California, San Francisco	—
Completed	Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia NCT01093365	Centre for Addiction and Mental Health	Phase 2
Active Not Recruiting	Database Registry for Neural Network Biomarkers in Psychosis NCT01409109	University of Texas Southwestern Medical Center	—
Completed	Prevention of Weight Gain in Early Psychoses NCT01075295	Centre for Addiction and Mental Health	N/A
Completed	Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis NCT01570972	University of Arizona	N/A
Completed	Remediation of Working Memory in Schizophrenia NCT00995553	VA Office of Research and Development	N/A
Completed	Study of Vitamin D in the Severely Mentally Ill NCT01169142	Bronx Psychiatric Center	Phase 4
Completed	Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia NCT01029769	Technical University of Munich	N/A
Completed	Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia NCT00728728	VA Office of Research and Development	Phase 2

Showing the 300 most recent trials. Use search for older records.